Trial · NCT06542887
Black Seed Oil in ADHD
NCT06542887, Phase 2, Unknown, Ain Shams University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Black Seed Oil in ADHD. Trials, record NCT06542887. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06542887
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Black Seed Oil in ADHD
- NCT number
- NCT06542887
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Ain Shams University
- Conditions
- ADHD
- Interventions
- Atomoxetine, Black Seed Oil Cap/Tab
- First posted
- 2024-08-07
- Last updated
- 2024-08-09
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Serum Glutathione Perioxidase | 3 months | Blood samples will be withdrawn from each patient at baseline and after 12 weeks. Samples will be centrifuged, and the sera will be separated and stored at -80°C till analysis. Serum GPx will be measured using human GPx ELISA kit at baseline and after 12 weeks. |
| Secondary | NICHQ Vanderbilt Assessment Scale-PARENT Informant | 3 months | The symptoms and severity of ADHD will be assessed using NICHQ Vanderbilt Assessment Scale-PARENT Informant for children aged 6-12 at baseline and after 12 weeks. The initial assessment scale has a total of 55 items in two components: symptom assessment and impairment in performance. Symptom assessment screens for symptoms that meet criteria for both inattentive (1-9) and hyperactive (10-18) ADHD. Also screens for symptoms of three other co-morbidities: oppositional defiant (19-26), conduct (27-40), and anxiety/depression (41-47). A positive response in symptom screens is a 2 or 3 (often, very often). The second section of the scale has a set of performance measures (48-55), scored 1 to 5, with 4 and 5 being somewhat of a problem/problematic. To meet the DSM-5 criteria for ADHD diagnosis, one must score 2 or 3 on at least 6 out of either the inattentive 9 or hyperactive 9 core symptoms or both and score 4 or 5 on any of the performance questions. |
| Secondary | Child Health Questionnaire Parent Form 28 item (CHQ-PF28) | 3 months | To assess the impact of ADHD on quality of life, Child Health Questionnaire Parent Form 28 item (CHQ-PF28) will be completed by parents at baseline and after 12 weeks. The CHQ-PF28 measures the following scales: Physical Functioning (3 items), Role functioning: emotional/behavior (1 item), Role functioning: physical (1 item), Bodily Pain (1 item), General Behavior (4 items), Mental Health (3 items), Self Esteem (3 items), General Health (4 items), Change in Health (1 item), Parental Impact-Emotional (2 items), Parental Impact-Time (2 items), Family Activities (2 items), and Family Cohesion (1 item). Response options vary from four to six levels for the scales. Per scale, the items are summed up and transformed into a scale from 0 (worst possible score) to 100 (best possible score), yielding two summary component scores of physical (PhS) and psychosocial (PsS) health. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06542887
GET https://conductscience.org/api/trials/v1/NCT06542887/registered